As part of its strategic review and second-quarter 2017 financial reporting, Ardelyx announced the company planned to cut 28 percent of its workforce.

Fremont, Calif.-based Ardelyx announced that its Phase III clinical trial of tenapanor for hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis met its primary endpoint.